Taken together, these findings suggest that palbociclib prompts the regulation of pro-inflammatory mediators in CAFs via GPER, which is engaged in the functional interaction between BC cells and these main components of the tumor stroma toward a reduced palbociclib sensitivity. The gene discussed is GPER1; the disease is breast cancer.